Gain Therapeutics, Inc. GANX 深 沪
等待开盘 05-19 09:30:00 美东时间
1.62
-0.130
-7.43%
华盛通- 最 高1.805
- 今 开1.76
- 成交量 100.38万股
- 最 低 1.585
- 昨 收 1.75
- 总市值 6909.95万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 2.35%
- 52周最低 1.41
- 委 比 99.14%
- 总股本 4265.40万
- 历史最高 17.93
- 量 比 2.22
- 振 幅 12.57%
- 历史最低 0.89
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported Q1 2026 financial results, highlighting increased R&D and G&A expenses due to GT-02287 development and currency fluctuations. The company presented promising Phase 1b data for GT-02287, showing biomarker improvements and stable MDS-UPDRS scores, supporting its disease-modifying potential for Parkinson's disease. GT-04686 also demonstrated activity in preclinical models. Upcoming milestones include IND clearance for GT-0...
05-11 11:00
Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an
04-24 20:33
Gain Therapeutics to give oral presentation at International GBA1 Meeting 2026
Gain Therapeutics to give oral presentation at International GBA1 Meeting 2026 Gain Therapeutics will give an oral presentation on GT-02287 development for Parkinson’s disease at 3rd International GBA1 Meeting on May 22, 2026, in Phoenix, Arizona. Company management will attend 7th World Parkinson’s
04-24 20:33
Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is unchanged from the same period last year.
03-26 19:14
Gain Therapeutics to Present at the 38th Annual ROTH Conference
Gain Therapeutics, Inc. announced that CEO Gene Mack will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference on March 22-24, 2026, in Dana Point, CA. The fireside chat will take place on March 23, 2026, at 11:30 a.m. PT. Gain is a clinical-stage biotech company focused on next-generation allosteric therapies, with its lead candidate GT-02287 in a Phase 1b trial for Parkinson’s disease and potential for other...
03-19 20:57
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
Gain Therapeutics ( ($GANX) ) has issued an announcement. On March 18, 2026, Ga...
03-18 21:44
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics announced presentations at the AD/PD 2026 conference on GT-02287, a potential disease-modifying therapy for Parkinson’s disease. Initial Phase 1b results will be shared, highlighting CNS target engagement and early clinical improvements. The company expects to initiate a Phase 2 trial in 3Q26 after submitting additional preclinical data to the FDA. GT-02287 aims to restore GCase enzyme function, addressing a key pathological dri...
03-12 11:00
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Gain Therapeutics的管理层将参加Oppenheimer的第36届年度医疗保健生命科学会议，并于2月25日下午1:20 ET参与炉边聊天。会议详情和回放可通过公司网站获取。投资者可联系Oppenheimer代表安排一对一会议。该公司专注于开发下一代变构疗法，其主要候选药物GT-02287正在针对帕金森病及其他神经退行性疾病进行临床试验。Gain利用其Magellan平台加速药物发现，致力于解决难治性疾病。
02-19 12:00
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics announced its participation in several key events during the 44th Annual J.P. Morgan Healthcare Conference, including the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase, and the LifeSci Advisors Corporate Access Event. The company highlighted its lead drug candidate, GT-02287, which is in clinical development for treating Parkinson’s disease with or without a GBA1 mutation. GT-02287 is an allosteri...
01-07 12:00
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics announced positive results from its Phase 1b clinical study of GT-02287 for Parkinson's disease (PD). In patients with elevated cerebrospinal fluid (CSF) glucosylsphingosine (GluSph), levels decreased by 81% after 90 days of treatment, indicating increased GCase enzyme activity and potential disease modification. Of the 19 participants, 15 showed average improvements in Movement Disorder Society Unified Parkinson’s Disease Ratin...
01-06 12:00
